Bronchogen

What is Bronchogen?

Bronchogen is a synthetic tetrapeptide consisting of alanine, glutamic acid, aspartic acid, and leucine (Ala-Glu-Asp-Leu, or AEDL), developed as part of Vladimir Khavinson's short peptide bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a Cytogen — a lab-synthesized short peptide based on a short sequence that the Khavinson group reports detecting by mass spectrometry in Langopept, a peptide preparation made from bronchial tissue, with its principal biological target being the respiratory epithelium and deeper lung tissue. Within the Khavinson respiratory pair, Bronchogen (AEDL) is framed as aimed at bronchial epithelial cell differentiation and maintenance, and is commonly discussed alongside Chonluten (EDG tripeptide), which is positioned more for stress-protective and anti-inflammatory gene regulation in the same tissue. In Russia, Bronchogen is sold as an oral capsule registered as a biologically active food supplement rather than a medicine, with each 0.2 g capsule listing 100 micrograms of the peptide complex; Western users mostly buy it from research-chemical vendors.

What Bronchogen Is Investigated For

Bronchogen is a Khavinson-program tetrapeptide investigated for bronchial epithelial maintenance, mucin gene regulation, and adjunct use in chronic bronchitis and COPD within the Russian bioregulator framework. The strongest mechanistic evidence is preclinical: peer-reviewed work from the Khavinson group reporting that the AEDL tetrapeptide regulates expression of bronchial epithelial genes — including the thyroid transcription factor NKX2-1 and the mucin genes MUC4 and MUC5AC — in cultured human embryonic bronchial epithelial cells, supported by small rat studies of nitrogen-dioxide-induced COPD and of bacterial, fibrotic and high-oxygen lung injury. The central honest caveat is that Western replication is absent, no randomized controlled trials are indexed in Western databases, and the only Bronchogen-specific human data is an unpublished, manufacturer-reported 2007 add-on study in chronic bronchitis with an asthmatic component that gives no patient numbers or between-group statistics. The proposed mechanism of direct DNA interaction by a tetrapeptide remains debated. Bronchogen is not FDA-approved, is not a recognized US dietary supplement ingredient (although Russia registers it as a dietary supplement), and should not substitute for evidence-based management of COPD, asthma, or chronic bronchitis.

History & Discovery

Bronchogen comes out of Vladimir Khavinson's peptide bioregulator program, which began at the Kirov Military Medical Academy (where tissue-extract drugs such as Thymalin and Epithalamin were developed in the 1980s–90s) and continued at the St. Petersburg Institute of Bioregulation and Gerontology, source of synthetic short peptides such as Epithalon, Livagen, Cortagen and the broader Cytogen / Cytomax series. According to Khavinson's 2020 review, the group used high-sensitivity chromatography-mass spectrometry to find two short peptides in Langopept, a bronchial-tissue peptide preparation: the tripeptide EDG (named Chonluten) and the tetrapeptide Ala-Glu-Asp-Leu (named Bronchogen). The synthetic tetrapeptide was patented in Russia (priority June 2004) and the US (US 7,625,870, granted December 2009) for restoring respiratory function after bacterial lung inflammation, fibrosis and toxic lung injury. The same review says that after preclinical testing Bronchogen was submitted to the Russian Ministry of Health for registration as a medicine; it is currently sold as a dietary supplement. Within the respiratory branch of the catalog, Bronchogen is paired with Chonluten (Glu-Asp-Gly), with Bronchogen positioned as aimed at bronchial epithelial cell differentiation and mucin-producing machinery and Chonluten aimed more at stress-protective and anti-inflammatory gene programs in the same tissue. The indexed footprint for Bronchogen is real but small: cell-model studies reporting AEDL regulation of NKX2-1 and the MUC4 / MUC5AC mucin genes, review articles placing AEDL within the broader Khavinson respiratory framework, rat studies of lung injury and nitrogen-dioxide COPD, test-tube DNA- and histone-binding work, and an unpublished, manufacturer-reported 2007 add-on study in chronic bronchitis with an asthmatic component. No new lung study of AEDL has been indexed in PubMed since 2017; the most recent AEDL research is in plant biology, where a Moscow agricultural biotechnology group reports that it stimulates tobacco root growth. As with the rest of the Khavinson lineup, this work is concentrated in Russian laboratories (the rat COPD studies come from a separate pulmonology team), has not been replicated by Western respiratory biology laboratories, and has not generated Western-standard controlled clinical trial data for any defined respiratory indication. Bronchogen reaches Western users almost exclusively through imported Russian oral capsules and through research-chemical lyophilized vials, neither of which represents validated therapeutic use.

How It Works

Bronchogen is a small four-amino-acid peptide proposed to enter bronchial and lung cells and help regulate the genes that keep the airway lining healthy. The Khavinson group reports that it changes the activity of genes involved in bronchial epithelial maintenance, including mucin production and lung-specific transcription factors, which is theorized to support airway function as the respiratory system ages or becomes chronically inflamed.

Bronchogen (Ala-Glu-Asp-Leu) is proposed to penetrate cell membranes due to its small molecular size and interact with DNA regulatory regions in respiratory epithelial cells. In cultured human embryonic bronchial epithelial cells, the Khavinson group reports that AEDL regulates expression of the thyroid transcription factor NKX2-1 (TTF-1), a master regulator of lung and bronchial epithelial differentiation, and activates the mucin genes MUC4 and MUC5AC, which encode components of the airway mucus barrier. The same 2014 study also reports effects on SCGB1A1, SCGB3A2, FOXA1, FOXA2 and the surfactant gene SFTPA1 and on the proliferation markers Ki67 and Mcl-1, most strongly in older, late-passage cultures. For AEDL specifically, test-tube studies report binding in the DNA major groove at guanine N7, a rise of about 3 °C in DNA melting temperature, loosening of nucleosome cores in liver chromatin, and binding to wheat histones. They disagree on what sequence it prefers: CTG- or CNG-containing sequences in fluorescence studies, a ctcc site in a docking model, and no AT or GC preference in a calorimetry study. In aging bronchial cell cultures, the group links AEDL's effects on NKX2-1 and SCGB1A1 to changes in promoter DNA methylation. Computer docking from the same program ranks AEDL among the stronger predicted binders of the LAT1, LAT2 and PEPT1 transporters, proposed (but not measured in cells) as a cellular uptake route for short bioregulator peptides, supporting systemic accessibility of the respiratory epithelium after oral or parenteral dosing. Within the originating group's framing, Bronchogen is paired functionally with Chonluten (Glu-Asp-Gly), which is described as contributing anti-inflammatory and stress-protective gene regulation (c-Fos, HSP70, SOD, COX-2, TNF-alpha) in the same tissue. Independent Western replication of the AEDL-specific gene regulation signal has not been published, and the 'direct DNA interaction by a tetrapeptide' component of the model remains contested outside the Khavinson research orbit.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Bronchogen:

• 01No randomized controlled trial of Bronchogen has been published or registered on ClinicalTrials.gov; the only human data is an unpublished 2007 manufacturer report without patient numbers or between-group statistics.
• 02The papers do not agree on the sequence label: the key 2014 Lung study and a 2011 DNA study print the peptide as Ala-Asp-Glu-Leu (ADEL), while the patent and later reviews use Ala-Glu-Asp-Leu (AEDL), and none explains the difference.
• 03The rat COPD findings (less goblet cell hyperplasia and neutrophilic inflammation after nitrogen-dioxide exposure) come from one Russian team and have not been repeated in other COPD models or outside Russia, and they sit uneasily with the cell-culture report that AEDL activates the mucin gene MUC5AC.
• 04The in vitro signal that AEDL upregulates NKX2-1, MUC4, and MUC5AC has not been independently replicated by bronchial epithelial biology laboratories outside the Khavinson research orbit, leaving the central mechanistic claim single-source.
• 05The AEDL-DNA binding studies disagree on what the peptide recognizes (CTG- or CNG-containing sequences, a ctcc site, or no AT/GC preference), all were done in test tubes or computer models, and none has shown binding at specific gene promoters inside living respiratory cells.
• 06No human pharmacokinetic data meeting Western regulatory standards exists for oral or injectable Bronchogen, so oral bioavailability, plasma half-life, tissue distribution to bronchial epithelium, and dose-response relationships are all unmeasured.
• 07Whether any in vitro gene-regulation effect of AEDL translates to measurable bronchoalveolar biomarkers (sputum mucin composition, airway inflammation markers, lung function indices) in humans has not been formally tested.
• 08Long-term safety of repeated chromatin- and transcription-level modulation in aging or chronically inflamed respiratory epithelium is unknown, including any theoretical oncologic consequence of chronically altering NKX2-1, a gene amplified as a lineage oncogene in some lung cancers, in at-risk lung tissue.
• 09Whether Bronchogen offers any incremental benefit over standard guideline-directed care in COPD, asthma, or chronic bronchitis has not been tested against a placebo or active comparator in a controlled design, leaving its real-world adjunct value unverified.

Forms & Administration

Bronchogen is sold in Russia as an oral dietary-supplement capsule (0.2 g, listing 100 micrograms of a peptide complex of alanine, glutamic acid, aspartic acid and leucine). The 2007 manufacturer report used 1–2 capsules twice daily for 20–30 days, and Russian sellers typically suggest monthly courses repeated after 4–6 months. Research-chemical vendors sell lyophilized vials, but no injected dose has ever been studied in people; the only published injected doses are from rats (0.2 micrograms per kg into the abdominal cavity daily for 7 days, in the developers' patent). All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Common Questions

Who Bronchogen Is NOT For

Drug & Supplement Interactions

No formal drug-interaction studies have been conducted with Bronchogen, and the Khavinson clinical literature does not characterize it against the cytochrome P450, transporter, or pharmacodynamic interaction frameworks used in Western drug development. Theoretical considerations follow from the proposed mechanism rather than from observed events. If the in vitro signal that AEDL upregulates the mucin genes MUC4 and MUC5AC translates to humans, concurrent use with mucolytic or mucoactive agents (N-acetylcysteine, carbocisteine, ambroxol, hypertonic saline) is conceptually relevant but uncharacterized — direction and magnitude of any net mucus-handling effect are unknown. Notably, in rats with nitrogen-dioxide-induced COPD, Bronchogen reduced goblet cell hyperplasia (the mucus-cell overgrowth typical of COPD), so the cell-culture mucin-gene signal does not simply mean more mucus. Because the only clinical report describes Bronchogen as an add-on to standard chronic bronchitis therapy of that era, the closest thing to a clinical interaction signal is in that context, not against modern inhaled corticosteroid / LABA / LAMA regimens. The proposed LAT-family amino acid transporter uptake route is shared by other Khavinson short peptides, leaving open a theoretical competition or additive-load consideration when multiple bioregulators are stacked, but this has not been measured. Patients on inhaled corticosteroids, long-acting bronchodilators, biologics for severe asthma, immunosuppressants, or any oncologic therapy should treat Bronchogen as an unknown variable and discuss it with the prescribing clinician before use rather than assume the absence of indexed interaction reports means absence of interaction.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions